Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Satricabtagene autoleucel by CARsgen Therapeutics for Gastric Cancer: Likelihood of Approval
Satricabtagene autoleucel is under clinical development by CARsgen Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData,...
Data Insights
Satricabtagene autoleucel by CARsgen Therapeutics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Satricabtagene autoleucel is under clinical development by CARsgen Therapeutics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction....